|
An Open-label Extension Study for Participants who Completed Study IMVT-1401-3201 or Study IMVT-1401-3202 to Assess the Efficacy and Safety of Batoclimab for the Treatment of Thyroid Eye Disease (TED)
University of Colorado Hospital Study IMVT-1401-3203 is a 2-cohort extension study for eligible participants completing the Week 24 visit on the feeder studies, IMVT-1401-3201 or IMVT-1401-3202. Participants will be assessed as proptosis responders or non-responders at Week 24 in the feeder studies. Based upon this as... |
|
IMVT-1401-3201: A Phase 3, Multi-center, Randomized, Quadruple-masked, Placebo-controlled Study of Batoclimab for the Treatment of Participants with Active Thyroid Eye Disease (TED)
University of Colorado Hospital Study IMVT-1401-3201 is a Phase 3, multi-center, randomized, quadruple‑masked (Sponsor, Investigator, assessor, and participant), placebo‑controlled study was designed to assess the efficacy and safety of batoclimab in adult participants with active, moderate to severe TED. The study durat... |
|
A multicenter, observational study to evaluate corneal neurosensory abnormalities in patients with Sjögren's dry eye
University of Colorado Hospital This clinical study has been designed to evaluate the proportion of patients with confirmed Sjögren's dry eye who present with neurosensory abnormalities via demonstration of increased ocular pain and/or a decrease in corneal sensitivity.... |
|
An Observational Study in Subjects to Follow the Progression of
Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic
Autosomal Recessive Mutations in the ATP Binding Cassette
Subfamily A Member 4 (ABCA4) Gene
(POLARIS)
University of Colorado Hospital This is a prospective, observational, non-interventional, multi-center, global clinical study of subjects with early to advanced stage STGD1 caused by bi-allelic likely pathogenic or pathogenic variants in the ABCA4 gene, confirmed genotypically by an accredited genotyping laboratory. T... |
|
Stress Response to Glaucoma Visual Field Testing
Outpatient CTRC, University of Colorado Hospital The primary outcome measures will be change in heart rate, blood pressure, salivary cortisol levels, and state anxiety pre- and post-visual field testing and the difference in these responses between HVF and VRVF... |